BACKGROUND: Poorly differentiated and anaplastic thyroid carcinomas have a rather poor prognosis. The development of relevant model systems to unravel in vitro and in vivo the molecular mechanisms governing the resistance of these tumors to therapy, as well as to test novel drug combinations, is a clear priority for thyroid-focused research. METHODS: Several novel cell lines were established from tumors developed by mice engineered to simultaneously express a loss-of-function Pten allele and an oncogenic Kras allele. RESULTS: Similar to most poorly differentiated thyroid tumors, these cell lines are characterized by simultaneous activation of the PI3K and MAPK pathways, by the presence of wild-type, functional p53, and by the severe downregulation of thyroid differentiation markers, including sodium-iodide symporter (NIS). Further, they display a highly glycolytic phenotype. They can be grafted to syngeneic, immunocompetent hosts, and easily metastasize to the lungs. CONCLUSIONS: These mouse cell lines are a novel and invaluable tool that can be used to develop innovative therapeutic approaches to poorly differentiated carcinomas in a more physiological context than using xenografts of human cell lines in immunocompromised mice.
BACKGROUND: Poorly differentiated and anaplastic thyroid carcinomas have a rather poor prognosis. The development of relevant model systems to unravel in vitro and in vivo the molecular mechanisms governing the resistance of these tumors to therapy, as well as to test novel drug combinations, is a clear priority for thyroid-focused research. METHODS: Several novel cell lines were established from tumors developed by mice engineered to simultaneously express a loss-of-function Pten allele and an oncogenic Kras allele. RESULTS: Similar to most poorly differentiated thyroid tumors, these cell lines are characterized by simultaneous activation of the PI3K and MAPK pathways, by the presence of wild-type, functional p53, and by the severe downregulation of thyroid differentiation markers, including sodium-iodide symporter (NIS). Further, they display a highly glycolytic phenotype. They can be grafted to syngeneic, immunocompetent hosts, and easily metastasize to the lungs. CONCLUSIONS: These mouse cell lines are a novel and invaluable tool that can be used to develop innovative therapeutic approaches to poorly differentiated carcinomas in a more physiological context than using xenografts of human cell lines in immunocompromised mice.
Authors: Sofia Asioli; Lori A Erickson; Alberto Righi; Long Jin; Marco Volante; Sarah Jenkins; Mauro Papotti; Gianni Bussolati; Ricardo V Lloyd Journal: Mod Pathol Date: 2010-06-18 Impact factor: 7.842
Authors: Kelly A Miller; Nicole Yeager; Kristen Baker; Xiao-Hui Liao; Samuel Refetoff; Antonio Di Cristofano Journal: Cancer Res Date: 2009-04-07 Impact factor: 12.701
Authors: Young H Ko; Barbara L Smith; Yuchuan Wang; Martin G Pomper; David A Rini; Michael S Torbenson; Joanne Hullihen; Peter L Pedersen Journal: Biochem Biophys Res Commun Date: 2004-11-05 Impact factor: 3.575
Authors: Kristen Wong; Francesca Di Cristofano; Michela Ranieri; Daniela De Martino; Antonio Di Cristofano Journal: Endocr Relat Cancer Date: 2019-01-01 Impact factor: 5.678
Authors: Daniela De Martino; Emrullah Yilmaz; Arturo Orlacchio; Michela Ranieri; Ke Zhao; Antonio Di Cristofano Journal: Cancer Lett Date: 2018-09-19 Impact factor: 8.679
Authors: Valeria G Antico Arciuch; Marika A Russo; Mariavittoria Dima; Kristy S Kang; Florence Dasrath; Xiao-Hui Liao; Samuel Refetoff; Cristina Montagna; Antonio Di Cristofano Journal: Oncotarget Date: 2011-12
Authors: Arturo Orlacchio; Michela Ranieri; Martina Brave; Valeria Antico Arciuch; Toni Forde; Daniela De Martino; Karen E Anderson; Phillip Hawkins; Antonio Di Cristofano Journal: Cancer Res Date: 2017-10-20 Impact factor: 12.701